Serum Neutrophil Gelatinase-Associated Lipocalin as a Marker of Renal Function in Non-Diabetic Patients with Stage 2–4 Chronic Kidney Disease

Renal Failure ◽  
2008 ◽  
Vol 30 (6) ◽  
pp. 625-628 ◽  
Author(s):  
Jolanta Malyszko ◽  
Hanna Bachorzewska-Gajewska ◽  
Ewa Sitniewska ◽  
Jacek S. Malyszko ◽  
Boguslaw Poniatowski ◽  
...  
2007 ◽  
Vol 22 (1) ◽  
pp. 101-108 ◽  
Author(s):  
Mark M. Mitsnefes ◽  
Thelma S. Kathman ◽  
Jaya Mishra ◽  
Janis Kartal ◽  
Philip R. Khoury ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Cheng-Kai Hsu ◽  
Tai-Shuan Lai ◽  
Yih-Ting Chen ◽  
Yi-Ju Tseng ◽  
Chin-Chan Lee ◽  
...  

AbstractAssociations between hepatitis C virus (HCV) and chronic kidney disease (CKD) have been reported; however, differences of renal progression between general and CKD population remain to be elucidated in prospective studies. A total of 1179 participants, who have tested for anti-HCV antibody, were enrolled and prospectively followed for 3 years. The risks associated with HCV infection, in terms of incidence of CKD, annual estimated glomerular filtration rate (eGFR) changes and 50% decline of eGFR at 3-year from baseline, were compared between normal renal function subjects and CKD patients. Overall, 111 of 233 (47.6%) CKD patients and 167 of 946 (17.7%) non-CKD subjects had HCV infection. The crude incidence rates of CKD were 226.9 per 1000 person-years and 14.8 per 1000 person-years in in HCV and non-HCV infected patients, respectively. The adjusted hazard ratio of HCV infection for incident CKD was 7.9 (95% CI 5–12.7). The HCV-infected normal renal function subjects were independently associated with increased risks of eGFR decline in the 1-year, 2-year and 3-year, respectively. The risk associations remained significant in 50% decline of eGFR at 3 years models and in different subgroup analyses. The increases of risks of eGFR decline were also notorious among overall HCV-infected CKD patients. However, the risk associations were less prominent in subgroup analyses (elderly, women and diabetic patients). The findings highlighted the importance of viral diagnosis with not only prognostic but also public health implications for preserving kidney function.


2008 ◽  
Vol 31 (4) ◽  
pp. 255-258 ◽  
Author(s):  
Davide Bolignano ◽  
Antonio Lacquaniti ◽  
Giuseppe Coppolino ◽  
Susanna Campo ◽  
Adriana Arena ◽  
...  

2013 ◽  
Vol 30 (1) ◽  
pp. 81-88 ◽  
Author(s):  
Midori Hasegawa ◽  
Junichi Ishii ◽  
Fumihiko Kitagawa ◽  
Kazuo Takahashi ◽  
Hiroki Hayashi ◽  
...  

2021 ◽  
Vol 84 (1) ◽  
pp. 2017-2032
Author(s):  
Halla Mohamed Allam ◽  
Haidy Essam Eldin Ahmed Zidan ◽  
Mohamed Gomaa Abdelrehim ◽  
Amira Mohamed Hamed Hassan

UK-Vet Equine ◽  
2021 ◽  
Vol 5 (5) ◽  
pp. 195-204
Author(s):  
Rachel Gough ◽  
Kate McGovern

Chronic kidney disease is a rare disease in horses, unlike humans and companion animals where it is frequently encountered. There are multiple causes, although, since the disease typically presents late in the disease process, the instigating factor is often not ascertained. Clinical signs most commonly include weight loss, ventral oedema and polyuria-polydipsia. There is a need for more sensitive markers of renal damage or dysfunction so that the disease can be detected earlier in its course. Serum symmetric dimethylarginine and neutrophil gelatinase-associated lipocalin are potential biomarkers that are being investigated in this regard. Currently, once the diagnosis has been made, treatment is supportive only, with no options to halt the progression of the disease. Although this is a terminal condition, horses can be maintained with an adequate quality of life for several years after diagnosis in some cases.


Sign in / Sign up

Export Citation Format

Share Document